High-tech discovery methods so broadly embraced over the past decade haven't delivered expected gains in productivity. Phenomix Corp. thinks it will fare better by harnessing mouse models of disease, randomly mutagenizing genes, checking the resulting phenotypes for beneficial changes then tracking back to the gene.
1099 North Torrey Pines Road, Suite 160A
La Jolla, CA 92037
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The Belgian drugmaker is boosting its biologics capacity over the pond.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
